We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.50 | 0.51% | 99.50 | 98.00 | 101.00 | 99.50 | 99.00 | 99.00 | 76,012 | 09:57:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 115.70 | 84.05M |
TIDMDXRX
RNS Number : 4993U
Diaceutics PLC
06 April 2021
Diaceutics PLC
("Diaceutics" or the "Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces the issue of share options over ordinary shares of GBP0.002 each in the Company ("Share Options") to certain Directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan.
Share Options were granted as follows:
Name Number of Share Total no. of % of existing Effective Options granted ordinary shares issued share Grant date under option capital post grant Peter Keeling, CEO 73,542 253,542 0.30% 1 April 2021 ---------------- ---------------- ------------- -------------- Philip White, CFO 64,154 244,154 0.29% 1 April 2021 ---------------- ---------------- ------------- -------------- Ryan Keeling, CIO 64,154 244,154 0.29% 1 April 2021 ---------------- ---------------- ------------- -------------- Damian Thornton, COO and PDMR 64,062 166,766 0.20% 1 April 2021 ---------------- ---------------- ------------- -------------- Jordan Clark, CCO and PDMR 46,003 122,117 0.15% 1 April 2021 ---------------- ---------------- ------------- -------------- Susanne Munksted, PDMR 45,475 116,147 0.14% 1 April 2021 ---------------- ---------------- ------------- -------------- Other employees (36 persons) 534,581 869,811 1.03% 1 April 2021 ---------------- ---------------- ------------- --------------
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria is based upon the growth in Total Shareholder Return, measured using the average mid-market closing share price in the month immediately before the end of the Performance Period, plus any dividends declared and paid during the Performance Period. The growth in TSR will be measured against a base share price of 102.67p, being the average mid-market closing share price in the three days prior to 1 April 2021, when the options were issued. The exercise price of the Share Options is GBP0.002 per share which equates to the nominal value of the shares.
Following this grant, the total number of share options outstanding in the Company is 2,016,687, representing approximately 2.4% of its current issued share capital of 84,063,923.
Enquiries:
Diaceutics PLC www.diaceutics.com Peter Keeling, Chief Executive via Walbrook PR Officer Philip White, Chief Financial Officer Cenkos Securities plc (Nominated adviser and broker) +44 (0)207 397 8900 Callum Davidson / Giles Balleny Michael Johnson (Sales) Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com Anna Dunphy Mob: +44 (0)7876 741 001 Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - our Proprietary Diagnostic Network solution for the development and commercialisation of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides solutions to 36 of the world's leading pharmaceutical companies. DXRX - the Diagnostic Network (R) provides unrivalled access to deep analysis and insights from the world's largest repository of diagnostic testing data on one secure platform. www.diaceutics.com
About DXRX - The Diagnostic Network(R)
DXRX is Diaceutics' proprietary diagnostic network for precision medicine. DXRX is an end-to-end solution for the development and commercialisation of Precision Medicine diagnostics. The platform enables a vibrant marketplace where all stakeholders in Precision Medicine come to find trusted partners and collaborations in a secure, standardised way. DXRX provides access to a pipeline of global diagnostic testing data on one secure platform.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------------- a. Name Peter Keeling ----------------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------------- a. Position/Status Chief Executive Officer ------------------------------------- ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of GBP0.002 the financial each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- ----------------------------- Exercise price of GBP0.002 per share 73,542 ------------------------------------------------------------------------- ----------------- e. Date of the transaction 1 April 2021 ------------------------------------- ----------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------------- a. Name Philip White ----------------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------------- a. Position/Status Chief Financial Officer ------------------------------------- ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of GBP0.002 the financial each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code
------------------------------------- ----------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- ----------------------------- Exercise price of GBP0.002 per share 64,154 ------------------------------------------------------------------------- ----------------- e. Date of the transaction 1 April 2021 ------------------------------------- ----------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------------- a. Name Ryan Keeling ----------------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------------- a. Position/Status Chief Innovation Officer ------------------------------------- ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of GBP0.002 the financial each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- ----------------------------- Exercise price of GBP0.002 per share 64,154 ------------------------------------------------------------------------- ----------------- e. Date of the transaction 1 April 2021 ------------------------------------- ----------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------------- a. Name Damian Thornton ----------------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------------- a. Position/Status Chief Operating Officer ------------------------------------- ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of GBP0.002 the financial each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- ----------------------------- Exercise price of GBP0.002 per share 64,062 ------------------------------------------------------------------------- ----------------- e. Date of the transaction 1 April 2021 ------------------------------------- ----------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------------- a. Name Jordan Clark ----------------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------------- a. Position/Status Chief Technology Officer ------------------------------------- ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of GBP0.002 the financial each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- ----------------------------- Exercise price of GBP0.002 per share 46,003 ------------------------------------------------------------------------- ----------------- e. Date of the transaction 1 April 2021 ------------------------------------- ----------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------------- a. Name Susanne Munksted ----------------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------------- a. Position/Status Managing Director and PDMR ------------------------------------- ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of GBP0.002 the financial each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- ----------------------------- Exercise price of GBP0.002 per share 45,475 ------------------------------------------------------------------------- ----------------- e. Date of the transaction 1 April 2021 ------------------------------------- ----------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- -----------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
IOEBGGDSCGGDGBL
(END) Dow Jones Newswires
April 06, 2021 06:12 ET (10:12 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions